65,437 trials
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 8 - On-treatment Analysis — -17.3; -66.2; -73.2 percent change — p=<0.0001
Cancer
Primary: Evaluation of Overall Survival — 50.4 weeks
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis — -2.7; -54.8; -62.3; -71.7 percent change — p=<0.0001
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis — -5.1; -39.6; -64.2; -72.4 percent change — p=<0.0001
Chronic Kidney Disease Stage 5
Primary: Change of Kidney Disease Quality of Life Short Form 1.3 (KDQOL SF 1.3) Score and Beck Depression Inventory(BDI) Score From Visit 1 Period — 1.22; -1.50; 1.62; 0.46 units…
Healthy Apheresis Donors · Mononuclear (MNC) Cell Donors
Primary: CD34+ Collection Efficiency (CE1 %) — 87.7; 81.4; 66.6; 65.8 percent
Hepatocellular Carcinoma
Primary: Recurrence Free Survival(RFS) — 44.0; 30.0 months — p=0.01
Leukemia · Fungal Infection
Primary: Maximum Observed Concentration in Plasma (Cmax) — 200; 290; 300; 580 ng/ml
Myopia
Primary: Comfort at Insertion — 9.21; 8.22 units on a scale
Healthy Volunteer, Female, Breast
Primary: Log Ratio of Post-baseline to Baseline Ki-67 Index in Mammary Epithelial Cells — 0.084; -0.100; -0.081 log ratio — p=0.2966
Wound Healing
Primary: Percentage of Wounds With Complete Skin Graft Take — 80; 78 percentage of wounds — p=0.80
Healthy
Primary: AUC(0-∞) for Empagliflozin — 4330; 4110; 1680; 1630 nmol * h/L — p=0.0000
Diabetes Mellitus Type 2
Primary: Health Related Quality of Life as Measured by the Short Form 36 Version 2 Questionnaire — 69.2; 72.5; 74.9; 77.1 units on a scale (General health score)
Neuroblastoma
Primary: Area Under the Plasma Concentration Curve (AUC) — 518; 470 mcg*hr/mL
Chronic Plaque Psoriasis
Primary: Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index)…